| Discovery | Multi-centre, adaptive, randomised trial of the safety and efficacy of treatments of Covid-19 in hospitalised adults
| Clinical Trial
(NCT04315948 | INSERM
| Non-commercial: Hospital
|
| SOLAR study | A Phase IIIb, Randomized, Multicenter, Active-controlled,Parallelgroup, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine administered every two months from a Bictegravir/emtricitabine/tenofovir alfenamide Single Tablet Regimen in HIV-1 Infected Adults who are Virologically Suppressed | Clinical Trial
(NCT04542070)
(2020-002623-11)
| GSK | Commercial: Industry |
| InoTerm ASTONISH
| Efficacy, Safety and Tolerability of Nangibotide in Patients with Septic Shock. A Randomized, Double-blind, Placebo Controlled Dose Selection Study
| Clinical Trial
(NCT04055909)
(2018-004827-36) | INOTERM S.A
| Commercial: Industry |
| MK1439A-028 | Phase 2b, Double Blinded, Multicentre, Randomized study to assess the effect on central nervous system (CNS) toxicity of switching from Atripla (Efavirenz, tenofovir, emtricatabine) to MK-1439A (Doravine, Tenofovir, lamivudine) in virologically supressed subjects | Clinical Trial
(NCT02652260)
(2015-003617-18) | Merck | Commercial: Industry |
| Alfa-1 | A randomized double blind placebo- controlled, pilot trial of intravenous plasma-purified alpha 1 antitrypsin for severe COVID-19 illness
| Clinical Trial
(2020-001391-15)
| RCSI
| Non-commercial: Academic
|
| PEACHI | PEACHI - A Phase 1 study to assess the safety and immunogenicity of prime boost immunisations with vaccine candidates AdCh3NSmut1 and MVA-Nsmut in HIV-1 seropositive HCV-uninfected adults on antiretroviral therapy (ART) | Clinical Trial
(NCT02568332) | University of Oxford | Non-commercial: Academic |
| Gilead | A phase 3b, Randomized, Double Blind, swithc study to evaluate F/TAF in HIV-1 infected Subjects who are virologically suppressed on regimens containing ABC/3TC | Clinical Trial
(NCT02469246) | Gilead | Commercial: Industry |
| COGHIV | The effects of a 16 week aerobic exercise programme on cognitive function in people living with HIV: A Radnomised Controlled Trial | Observational-non invasive | N/A | Non-commercial: Academic |
| COGIMP | The Inflammatory Neurodegenerative Continuum in HIV Related Cognitive Impairment. Longitudinal Follow up of Cognitive Impairment in a Well Characterized Cohort of HIV Positive Patients | Observational-non invasive | N/A | Non-commercial: Academic |
